Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 127   

Articles published

ABT 38.93 +0.55 (1.43%)
price chart
Stocks to Watch: Abbott Labs, Bank of America, Yahoo
Abbott Laboratories said its first-quarter earnings fell 31% as the health-care products company reported negative currency impacts masked modest overall sales growth.
Abbott Laboratories profit beats forecast, but sales lag  CNBC.com
Related articles »  
Abbott Laboratories: This Company Has Potential To Expand Into Emerging ...
Equity researchers Jefferies Group, recently reiterated their buy rating for Abbott Laboratories' (ABT) stock. The stock is currently trading between $38-38.50 and the researchers have set a $45 price target.
Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories
In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT). In the report, Morgan Stanley noted, �The most challenging quarter of the year is behind ...
Related articles »  
Abbott Laboratories Enters Oversold Territory (ABT)
In trading on Thursday, shares of Abbott Laboratories Abbott Laboratories (NYSE: ABT) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $37.13 per share.
Related articles »  
Will Abbott Labs (ABT) Disappoint This Quarter?
Abbott Labs is an extremely diversified company with its presence in the diagnostics, nutrition, generics and medical devices markets after having separated its pharmaceutical business into a new company called AbbVie (ABBV - Analyst Report) in Jan 2013.
How Will This Earnings Report Affect Abbot Laboratories (ABT) Stock Today?
"We rate ABBOTT LABORATORIES (ABT) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for ...
Related articles »  
Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps
Sales across Abbott Labs' (NYSE: ABT ) four major business units grew less than 1% last quarter versus the same period a year ago.
Abbott Laboratories (ABT) Receives FDA 510(k) Clearance for HbA1c Test
Abbott (NYSE: ABT) announced that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test - which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease - has received 510(k) clearance from ...
Abbott Announces FDA Clearance for a New Test to Help Physicians Quickly ...  MarketWatch
Abbott Gets FDA Clearance For ARCHITECT Clinical Chemistry Hemoglobin ...  NASDAQ
Related articles »  
Abbott Laboratories Statement re Proxy Materials
The Company informs its shareholders that on 14 April 2014 and 14 March 2014, in accordance with the U.S. Securities Exchange Act of 1934, as amended, a definitive proxy statement and definitive additional proxy materials (the "Proxy Materials") were ...
Related articles »  
Abbott Earnings And Revenue Decrease, But I'm Still Going To Buy Cautiously
Since that article was published, the stock is up 1.08% on the back of earnings, while the S&P 500 (SPY) was up 1.05%. Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based healthcare ...
Related articles »